News & Press Releases Swedish

Scandinavian ChemoTech erhåller slutligt patentgodkännande i EU för den tumörspecifika kontrollenheten i vår TSE™-plattform

Företaget har fått det slutgiltiga godkännandet för sitt EU-patent som inkluderar den tumörspecifika kontrollenheten och säkerhetsfunktioner som är avgörande för vår TSE-plattform. Innovationen är utformad för att minska de biverkningar som normalt uppstår med äldre elektroporations- och ablativa tekniker.

Read more

Scandinavian ChemoTechs dotterbolag Vetiqure deltar vid ESVONCs kongress i Italien

Mellan den 26–28 maj 2022 kommer vår produktspecialist Elin Wallin samt vår VD Mohan Frick att delta vid ESVONCs årliga kongress i Italien där även en poster om behandling med vår TSE™-teknologi har accepterats och kommer att presenteras.

Read more

Scandinavian ChemoTechs dotterbolag Vetiqure AB installerar TSE och initierar behandlingar i USA

Vetiqure AB har genomfört utbildning och installation av TSE-terapin på FloridaWild Veterinary Hospital i Florida, USA.

Read more

News & Press Releases English

Scandinavian ChemoTech receives final patent approval in the EU for the tumour specific control unit in our TSE™ platform

The Company has received the final approval for its EU patent which includes the tumour specific control unit and safety features that are crucial for our TSE platform. The innovation is designed to reduce the side effects which normally occur with older electroporation and ablative technologies.

Read more

Scandinavian ChemoTech's subsidiary Vetiqure participates in ESVONC's congress in Italy

Between May 26–28th 2022, our product specialist Elin Wallin and our CEO Mohan Frick will participate in ESVONC's annual congress in Italy. A poster on treatment with our TSE™ technology has been accepted and will also be presented there.

Read more

Scandinavian ChemoTech’s subsidiary Vetiqure AB installs TSE and initiates treatments in USA

Vetiqure AB has conducted training and installation of the TSE therapy at FloridaWild Veterinary Hospital in Florida, USA.

Read more

Our foundation

Our profound knowledge in electroporation forms the starting point for the company’s existing product vetIQure™, specially desinged for TSE – Tumour Specific Electroporation – treating a range of different types of tumours in pets.

Our research focus

vetIQure™ is a new innovation in cancer care based on the patented technology Tumour Specific Electroporation (TSE) designed for safe and easy cancer treatment of animals. Our aim is to document the effects of elctrochemotherapy within an area with significant unmet medical need.

Meet our product specialist Elin!

Are you interested in our product? Then please contact us on info@vetiqure.se to book an appointment.